Freedom Investment Management Inc. Acquires New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Freedom Investment Management Inc. acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,581 shares of the biotechnology company’s stock, valued at approximately $220,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $750,000. Bayforest Capital Ltd purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $840,000. Bender Robert & Associates purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $212,000. Assenagon Asset Management S.A. boosted its stake in shares of BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after acquiring an additional 3,606,566 shares during the last quarter. Finally, Family Legacy Financial Solutions LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $72,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $7.31 on Tuesday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The firm’s fifty day moving average is $7.68 and its 200 day moving average is $8.68. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -40.61 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analysts’ expectations of $149.59 million. During the same quarter last year, the firm posted ($0.06) EPS. The firm’s quarterly revenue was up 49.5% compared to the same quarter last year. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

BCRX has been the topic of several analyst reports. Bank of America lifted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, July 1st. Evercore ISI reiterated an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Cantor Fitzgerald lifted their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. JMP Securities lifted their price target on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.18.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.